1. Furazabol does not aromatize and also has very minimal bloat. It has a moderately potent androgenic activity, giving it a fairly low risk for gyno or negative effects on the libido. However its androgenic effects may pose a problem for users prone to androgenic related hair loss.

once the Furazabol THP reaches the stomach, most of the THP-ether is removed by the stomach acid to form the active Furazabol (the non-methylated version). Therefore, topical delivery of this compound is probably not worthwhile. Furazabol has a similar structure to the illegal anabolic steroid stanozolol (Winstrol). The only difference is the pyrazole ring has been replaced with a furazan ring. There is rumor that this compound has benefits for cholesterol levels. While some evidence proves that it can lower total cholesterol, it should be noted that the decrease in cholesterol is mostly due to a decrease in HDL. Therefore, your LDL/HDL ratio would become worse.

2. Overall this compound produces mild gains, but the side-effects are very mild too. Noticeable gains in lean muscle mass and strength are likely not going to be achieved unless doses of at least 200mg/day are used. Furazabol is going to produce very little water retention, therefore it should produce a lean and vascular appearance. Big increases in weight are not likely to happen with this steroid either, so increased blood pressure and painful back pumps should not be a problem.

Furazabol (Miotolan) is a derivative of the anabolic steroid stanozolol. It differs from stanozolol by having a furazan ring system in place of  the pyrazole. It has a c-17alpha methyl group, which allows it to be taken orally and causes hepatotoxicity in some individuals.

According to William Llewellyn, author of Anabolics 2007, the cholesterol-lowering effects of furazabol are a myth. In the 1970s, research studies  showed that furazabol along with many other orally-active AAS like Anavar (oxandrolone) lowered total serum cholesterol.It was subsequently  established that the cholesterol reduction from oral AAS was the result of suppressed HDL levels. As such, it would be expected that furazabol,  like other oral anabolic steroids, while reducing total cholesterol levels would still adversely affect the HDL/LDL ratio and increase the risk of  cardiovascular disease.

The Canadian sprinter Ben Johnson tested positive for stanozolol after winning the gold medal in the 100 meter sprint at the 1988 Summer Olympics.  His doctor, Dr. Jamie Astaphan, maintains that his urine sample was sabotaged because Johnson was administered furazabol, which was not an IOC  banned substance at the time.Subsequently, training partner and fellow Charlie Francis athlete Angela Issajenko, in her book "Running  Risks" outlined a theory stating Ben Johnson actually was using stanozolol. She substantiated this by stating that her supply of what she thought  was furazabol was retested following the Dubin Inquiry and was found to be stanozolol, explaining the positive test.